PHC Holdings Corp. (6523) AI Stock Analysis

• Market Cap: ¥139.40B
• Dividend Yield: 3.73%
• Average Volume (3M): 164.09K
• Price to Earnings (P/E): 39.3
• Beta (1Y): 0.56
• Revenue Growth: 0.04%
• EPS Growth: N/A
• Country: JP
• Employees: 9,245
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): N/A
• Shares Outstanding: 126,724,020
• 10 Day Avg. Volume: 194,380
• 30 Day Avg. Volume: 164,093
• PEG Ratio: -0.07
• Price to Book (P/B): 0.91
• Price to Sales (P/S): 0.36
• P/FCF Ratio: 4.25
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: ¥1,052.00 ▼(-5.40% Downside)
• Action: Reiterated Date: 02/18/26
• Date: Action: Reiterated 02/18/26

The score is primarily driven by mixed financial performance: strong recent revenue growth and solid cash flow are offset by thin/volatile profitability and elevated leverage. Technicals are a notable headwind with weak momentum and the price below key moving averages, while valuation is balanced by a high P/E despite an attractive dividend yield.

Positive Factors

Accelerating Revenue Growth

TTM revenue growth of +78% indicates expanding demand and successful product uptake across diabetes, diagnostics and hospital segments. Sustained top-line expansion increases the installed base for consumables and services, drives recurring revenue potential and provides scale for margin and margin-investment improvements over the medium term.

Healthy Gross & EBIT Margins

A gross margin near 46% and positive EBIT margin (~7%) reflect structural pricing power and a favorable product mix in higher-value healthcare segments. These margins create operating leverage that can absorb SG&A and R&D, supporting durable cash generation and resilience to cyclical pressures over the next several months.

Strong Cash Generation

Robust operating cash flow (~¥41.5B) and free cash flow (~¥32.0B), with recent FCF growth, provide internal funding for capex, servicing debt, dividends and strategic investments. Reliable cash conversion reduces reliance on external financing and gives the company flexibility to deleverage or invest in product and geographic expansion over the medium term.

Negative Factors

Thin & Volatile Net Profits

A net margin of about 1.6% coupled with historical swings and losses in FY2022–FY2024 indicates fragile bottom-line conversion. Profit volatility weakens earnings quality and makes cash returns to shareholders and reinvestment plans less predictable, increasing risk if revenue growth slows or costs rise.

Elevated Leverage

Debt at roughly 1.7x equity, while improved, remains elevated and constrains financial flexibility. Higher leverage increases interest expense sensitivity and reduces room for strategic moves; in the event of margin compression or slower top-line momentum, the company could face tighter capital allocation and slower deleveraging.

Modest Return on Equity

TTM ROE of about 4% signals limited effectiveness in converting revenue and cash into shareholder returns. Persistently low ROE suggests capital intensity or operational inefficiencies that could hinder long-term shareholder value creation unless profitability or asset efficiency meaningfully improves.

PHC Holdings Corp. Business Overview & Revenue Model

Company Description

PHC Holdings Corporation, through its subsidiaries, develops, manufactures, and sells medical devices, healthcare technology solutions, and life science products. The company offers blood glucose monitoring systems and other testing/analysis devices, as well as data linkage solutions; anatomical pathology solutions, such as instruments, microscope slides, and dyeing reagents; and equipment and services for various sample preservation and cell culture in the life sciences field. It also provides healthcare IT products in the field of medical information systems for clinics and healthcare insurance pharmacies. In addition, the company engages in clinical testing, diagnostic reagents, and drug development support businesses. The company was formerly known as Panasonic Healthcare Holdings Co., Ltd. and changed its name to PHC Holdings Corporation in April 2018. The company was founded in 2014 and is headquartered in Tokyo, Japan.

How the Company Makes Money

PHC Holdings Corp. generates revenue through multiple key streams, primarily from the sale of medical devices and diagnostic products. The company offers a range of products including blood glucose monitoring systems, automated clinical analyzers, and other medical supplies that cater to hospitals, clinics, and healthcare providers. Additionally, PHC Holdings engages in research and development partnerships with other healthcare organizations, which not only enhances its product offerings but also contributes to revenue through collaborative projects and licensing agreements. The company's strategic focus on expanding its presence in emerging markets and investing in cutting-edge technology further drives its earnings, allowing it to tap into new customer segments and increase market share.

PHC Holdings Corp. Financial Statement Overview

Summary

Strong TTM revenue growth (+78%) and solid gross margin (~46%) support fundamentals, and cash generation is healthy. However, net profitability is thin (~1.6% net margin) and historically volatile, and leverage remains elevated (~1.7x debt-to-equity), limiting financial flexibility.

Income Statement

TTM (Trailing-Twelve-Months) revenue grew sharply (+78%), and gross margin remains solid (~46%). However, profitability is still thin at the bottom line (net margin ~1.6%) and has been volatile over the past few years (losses in FY2022–FY2024, profit in FY2025 and TTM). Operating profitability is positive (EBIT margin ~7%), but the earnings quality is not yet consistently strong given the recent swing in net income.

Balance Sheet

Leverage is elevated, with debt running about 1.7x equity in TTM (improving from ~2.0–3.0x in earlier years). Equity has been rebuilt versus prior years, but returns remain modest (TTM return on equity ~4%), reflecting limited net profitability. The balance sheet is workable, but the debt load reduces flexibility if margins weaken or growth slows.

Cash Flow

Cash generation is a relative strength: TTM operating cash flow (~¥41.5B) and free cash flow (~¥32.0B) are solid, and free cash flow growth is strong in the latest period. That said, free cash flow is still below net income in TTM (about 75%), and cash flow relative to revenue is not especially high, implying some ongoing working-capital or reinvestment demands.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	363.93B	361.59B	353.90B	356.43B	340.45B	306.07B
Gross Profit	164.69B	166.22B	157.97B	169.13B	165.24B	143.65B
EBITDA	50.52B	52.33B	30.15B	36.76B	37.56B	62.29B
Net Income	3.54B	10.48B	-12.89B	-3.22B	-8.46B	16.91B
Balance Sheet
Total Assets	552.67B	532.48B	564.33B	561.57B	591.32B	569.02B
Cash, Cash Equivalents and Short-Term Investments	49.03B	39.59B	51.82B	63.25B	97.63B	63.96B
Total Debt	246.45B	255.26B	285.05B	292.62B	307.94B	321.55B
Total Liabilities	394.05B	391.31B	425.16B	422.74B	455.26B	461.46B
Stockholders Equity	159.29B	141.64B	139.51B	138.01B	135.37B	107.02B
Cash Flow
Free Cash Flow	32.03B	30.33B	26.67B	9.86B	39.32B	35.70B
Operating Cash Flow	41.49B	41.94B	41.30B	21.38B	51.05B	47.85B
Investing Cash Flow	-8.05B	-8.47B	-21.07B	-17.52B	-12.52B	-16.31B
Financing Cash Flow	-30.96B	-39.07B	-39.14B	-40.83B	-7.01B	-20.39B

PHC Holdings Corp. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1112.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6523, the sentiment is Positive. The current price of 1112 is above the 20-day moving average (MA) of 1074.65, below the 50-day MA of 1112.70, and above the 200-day MA of 1003.95, indicating a neutral trend. The MACD of -10.51 indicates Negative momentum. The RSI at 54.17 is Neutral, neither overbought nor oversold. The STOCH value of 89.59 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:6523.

PHC Holdings Corp. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6678	78 Outperform	¥22.50B	17.62	―	3.02%	-4.36%	-14.92%
6823	69 Neutral	¥37.55B	12.60	―	2.93%	6.72%	20.01%
4549	68 Neutral	¥103.52B	27.01	―	2.31%	4.36%	79.43%
6849	65 Neutral	¥290.48B	22.94	―	1.92%	4.31%	96.31%
7600	58 Neutral	¥16.93B	-16.07	―	3.12%	3.59%	-163.08%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
6523	51 Neutral	¥139.40B	39.27	4.32%	3.73%	0.04%	―